

Title (en)

COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL CANCERS

Title (de)

KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON SOLIDEN UND HÄMATOLOGISCHEN BÖSARTIGEN TUMOREN

Title (fr)

POLYTHÉRAPIE POUR LE TRAITEMENT DE CANCERS SOLIDES ET HÉMATOLOGIQUES

Publication

EP 3600393 A4 20201223 (EN)

Application

EP 18771103 A 20180322

Priority

- US 201762475036 P 20170322
- US 201762475032 P 20170322
- US 201815871802 A 20180115
- US 2018023860 W 20180322

Abstract (en)

[origin: WO2018175790A1] Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, more specifically, chemotherapeutic agents, which include but are not limited to anthracyclines, platinum, taxol, topoisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, and alkylating agents.

IPC 8 full level

C07K 16/28 (2006.01); **A61K 35/28** (2015.01); **A61K 39/395** (2006.01); **C12N 5/0786** (2010.01)

CPC (source: EP US)

A61K 31/704 (2013.01 - EP US); **A61K 39/3955** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 1/00** (2017.12 - EP US); **A61P 3/10** (2017.12 - EP US); **A61P 5/38** (2017.12 - EP US); **A61P 7/06** (2017.12 - EP US); **A61P 9/00** (2017.12 - EP US); **A61P 9/10** (2017.12 - EP US); **A61P 17/06** (2017.12 - EP US); **A61P 19/02** (2017.12 - EP US); **A61P 21/04** (2017.12 - EP US); **A61P 25/28** (2017.12 - EP US); **A61P 35/00** (2017.12 - EP US); **A61P 35/02** (2017.12 - EP US); **A61P 37/02** (2017.12 - EP US); **C07K 16/2803** (2013.01 - EP US); **A61K 2039/505** (2013.01 - EP US); **C07K 2317/24** (2013.01 - EP US); **C07K 2317/33** (2013.01 - EP US); **C07K 2317/41** (2013.01 - EP US); **C07K 2317/526** (2013.01 - EP US); **C07K 2317/53** (2013.01 - EP US); **C07K 2317/55** (2013.01 - EP US); **C07K 2317/56** (2013.01 - US); **C07K 2317/565** (2013.01 - US); **C07K 2317/70** (2013.01 - EP US); **C07K 2317/71** (2013.01 - EP US); **C07K 2317/73** (2013.01 - EP US); **C07K 2317/732** (2013.01 - US); **C07K 2317/734** (2013.01 - US); **C07K 2317/76** (2013.01 - EP US); **C07K 2317/92** (2013.01 - EP US)

Citation (search report)

- [Y] US 2004073013 A1 20040415 - FUKUSHIMA NAOSHI [JP], et al
- [A] WO 2014123580 A1 20140814 - INHIBRX LLC [US]
- [XP] WO 2017049251 A2 20170323 - TIOMA THERAPEUTICS INC [US]
- [Y] PER-ARNE OLDENBORG: "CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease", ISRN HEMATOLOGY, 1 January 2013 (2013-01-01), pages 1 - 19, XP055663144, DOI: 10.1155/2013/614619
- [Y] ANA-CAROLINA MARTINEZ-TORRES ET AL: "CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLC[gamma]1 Activation: Evidence from Mice and Humans", PLOS MEDICINE, vol. 12, no. 3, 3 March 2015 (2015-03-03), pages e1001796, XP055318218, DOI: 10.1371/journal.pmed.1001796
- [Y] PETHA MANNA ET AL: "CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1026 - 1036, XP055030076, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-03-1708
- [XY] JESSICA LO ET AL: "Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma", LIVER INTERNATIONAL, vol. 36, no. 5, 1 May 2016 (2016-05-01), GB, pages 737 - 745, XP055505901, ISSN: 1478-3223, DOI: 10.1111/liv.12963
- [X] KATHAWALA: "Abstract 4001: The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy | Cancer Research", AACR 107TH ANNUAL MEETING 2016, vol. 76, 15 July 2016 (2016-07-15), XP055506116, DOI: 10.1158/1538-7445.AM2016-4001
- [I] XIAOJUAN LIU ET AL: "CD47 blockade triggers T cell-mediated destruction of immunogenic tumors", NATURE MEDICINE, vol. 21, no. 10, 31 October 2015 (2015-10-31), New York, pages 1209 - 1215, XP055478072, ISSN: 1078-8956, DOI: 10.1038/nm.3931
- [A] ROBERT W KARR: "Experimental data on anti-CD47 antibodies", OPPOSITION PROCEEDINGS RELATING TO EUROPEAN PATENT EP2242512, 20 January 2017 (2017-01-20), pages 1 - 11, XP055692350, Retrieved from the Internet <URL:https://register.epo.org/application?number=EP09701993&lng=en&tab=doclist> [retrieved on 20200506]
- See references of WO 2018175790A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2018175790 A1 20180927; AU 2018240377 A1 20191031; CA 3057139 A1 20180927; CN 111148535 A 20200512; EP 3600393 A1 20200205; EP 3600393 A4 20201223; JP 2020511481 A 20200416; JP 7170331 B2 20221114; SG 11201908602U A 20191030

DOCDB simple family (application)

US 2018023860 W 20180322; AU 2018240377 A 20180322; CA 3057139 A 20180322; CN 201880028490 A 20180322; EP 18771103 A 20180322; JP 2019551449 A 20180322; SG 11201908602U A 20180322